To determine the impact of subcutaneous secukinumab (Cosentyx, Novartis) in doses of 300 mg and 150 mg on the symptoms and radiographic progression of PsA, as well as whether there is a short-term ...

Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below 1.Justification for the choice of the negotiated ...

For more information about the common dosages of Cosentyx, see this detailed article. liquid solution inside single-dose prefilled injection pens 150 mg/mL and 300 mg/2 mL liquid solution inside ...

FDA 的批准基于迄今为止最大的 HS III 期项目 SUNSHINE 和 SUNRISE 的分析，其中每两周或每四周接受 Cosentyx 300 mg 治疗的患者中有较高比例达到化脓性汗腺炎临床缓解 (HiSCR50)与安慰剂相比。1用于 HS 的 Cosentyx 被批准为 300 mg 剂量，每四周给药一次，如果患者反应不足 ...

The FDA approval was based on analyses from the largest Phase III program in HS to date, SUNSHINE and SUNRISE, in which a higher proportion of patients given Cosentyx 300 mg either every two weeks or ...

The drug is approved as a 300 mg dose administered every 4 weeks, with the option to increase to every 2 weeks if the patient is unresponsive. The FDA has approved Cosentyx for the treatment of ...

The FDA approval was based on analyses from the largest Phase III program in HS to date, SUNSHINE and SUNRISE, in which a higher proportion of patients given Cosentyx 300 mg either every two weeks ...